Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Malar J ; 16(1): 57, 2017 01 31.
Artículo en Inglés | MEDLINE | ID: mdl-28143519

RESUMEN

BACKGROUND: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria. METHODS: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8-year, multicentre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria according to the 2006 WHO criteria. RESULTS: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were included. Three patients died, resulting in a 28-day survival rate of 98.4%. The majority of infections were acquired in West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post-artemisinin delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate. CONCLUSION: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infection in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous artesunate should be followed up to detect and manage late haemolytic events.


Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/epidemiología , Adulto , Anciano , Antimaláricos/clasificación , Europa (Continente)/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto Joven
2.
Clin Infect Dis ; 61(9): 1441-4, 2015 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-26187021

RESUMEN

Intravenous artesunate improves survival in severe malaria, but clinical trial data from nonendemic countries are scarce. The TropNet severe malaria database was analyzed to compare outcomes of artesunate vs quinine treatment. Artesunate reduced parasite clearance time and duration of intensive care unit and hospital treatment in European patients with imported severe malaria.


Asunto(s)
Antimaláricos/administración & dosificación , Artemisininas/administración & dosificación , Malaria/tratamiento farmacológico , Administración Intravenosa , Adulto , Artesunato , Europa (Continente) , Femenino , Humanos , Masculino , Quinina/administración & dosificación , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento
3.
Malar J ; 12: 35, 2013 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-23351608

RESUMEN

BACKGROUND: Chloroquine (CQ) was the main malaria therapy worldwide from the 1940s until the 1990s. Following the emergence of CQ-resistant Plasmodium falciparum, most African countries discontinued the use of CQ, and now promote artemisinin-based combination therapy as the first-line treatment. This change was generally initiated during the last decade in West and Central Africa. The aim of this study is to describe the changes in CQ susceptibility in this African region, using travellers returning from this region as a sentinel system. METHODS: The study was conducted by the Malaria National Reference Centre, France. The database collated the pfcrtK76T molecular marker for CQ susceptibility and the in vitro response to CQ of parasites from travellers' isolates returning from Senegal, Mali, Ivory Coast or Cameroon. As a proxy of drug pressure, data regarding CQ intake in febrile children were collated for the study period. Logistic regression models were used to detect trends in the proportions of CQ resistant isolates. RESULTS: A total of 2874 parasite isolates were genotyped between 2000-2011. The prevalence of the pfcrt76T mutant genotype significantly decreased for Senegal (from 78% to 47%), Ivory Coast (from 63% to 37%), Cameroon (from 90% to 59%) and remained stable for Mali. The geometric mean of the 50% inhibitory concentration (IC50) of CQ in vitro susceptibility and the proportion of resistant isolates (defining resistance as an IC50 value > 100 nM) significantly decreased for Senegal (from 86 nM (59%) to 39 nM (25%)), Mali (from 84 nM (50%) to 51 nM (31%)), Ivory Coast (from 75 nM (59%) to 29 nM (16%)) and Cameroon (from 181 nM (75%) to 51 nM (37%)). Both analyses (molecular and in vitro susceptibility) were performed for the 2004-2011 period, after the four countries had officially discontinued CQ and showed an accelerated decline of the resistant isolates for the four countries. Meanwhile, CQ use among children significantly deceased in this region (fixed effects slope = -0.3, p < 10-3). CONCLUSIONS: An increase in CQ susceptibility following official withdrawal of the drug was observed in travellers returning from West and Central African countries. The same trends were observed for molecular and in vitro analysis between 2004-2011 and they correlated to the decrease of the drug pressure.


Asunto(s)
Antimaláricos/uso terapéutico , Cloroquina/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Adolescente , Adulto , África Central , África Occidental , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Resistencia a Medicamentos , Femenino , Genotipo , Humanos , Lactante , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Pruebas de Sensibilidad Parasitaria , Plasmodium falciparum/genética , Plasmodium falciparum/aislamiento & purificación , Viaje , Adulto Joven
4.
Med Trop Sante Int ; 3(4)2023 12 31.
Artículo en Francés | MEDLINE | ID: mdl-38390022

RESUMEN

Warnings against predatory journals get stronger. Designed to capture manuscripts with the promise of rapid publication, the main aim of these journals is to charge abusive publication fees. Sometimes boasting imaginary impact factors, they are not indexed and offer no guarantee of visibility, accessibility or durability of the published article. Above all, they have no concern for the rigor and scientific integrity of the work they publish.


Asunto(s)
Honorarios y Precios , Conducta Predatoria , Animales
5.
J Fungi (Basel) ; 8(12)2022 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-36547591

RESUMEN

Mycetoma is a chronic, disabling infection caused by fungi or actinomycetes that affects the disadvantaged rural populations of arid tropical regions. The identification of etiological agents is long, difficult, and often imprecise or unsuccessful. Recently developed molecular methods can be used to identify causal agents at the species level. However, diagnosis can only be implemented in specialized laboratories. For these reasons, the distribution of causal agents in endemic African countries remains approximate. It is known that the pathogenic organisms of mycetoma are present in the environment, introduced as a result of injuries or trauma. There are still unknowns concerning the natural habitats of agents and the mode of infection. A potential association between mycetoma and acacia was uncovered in Sudan, allowing the elaboration of a risk map of the country. A new hypothesis for the mode of contamination involves the intervention of an intermediate host. The first surveys in Sudanese endemic villages gave a higher prevalence than the previous estimates, indicating that the prevalence of mycetoma in endemic African countries has previously been underestimated.

6.
PLoS Negl Trop Dis ; 15(5): e0009318, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33956817

RESUMEN

The Republic of Congo (RoC) is one of the African countries with the most histoplasmosis cases reported. This review summarizes the current status regarding epidemiology, diagnostic tools, and treatment of histoplasmosis in the RoC. A computerized search was performed from online databases Medline, PubMed, HINARI, and Google Scholar to collect literature on histoplasmosis in the RoC. We found 57 cases of histoplasmosis diagnosed between 1954 and 2019, corresponding to an incidence rate of 1-3 cases each year without significant impact of the AIDS epidemic in the country. Of the 57 cases, 54 (94.7%) were cases of Histoplasma capsulatum var. duboisii (Hcd) infection, African histoplasmosis. Three cases (5.3%) of Histoplasma capsulatum var. capsulatum infection were recorded, but all were acquired outside in the RoC. The patients' ages ranged between 13 months to 60 years. An equal number of cases were observed in adults in the third or fourth decades (n = 14; 24.6%) and in children aged ≤15 years. Skin lesions (46.3%), lymph nodes (37%), and bone lesions (26%) were the most frequent clinical presentations. Most diagnoses were based on histopathology and distinctive large yeast forms seen in tissue. Amphotericin B (AmB) was first line therapy in 65% of the cases and itraconazole (25%) for maintenance therapy. The occurrence of African histoplasmosis in apparently normal children raises the possibility that African histoplasmosis is linked to environmental fungal exposure.


Asunto(s)
Huesos/microbiología , Histoplasma/aislamiento & purificación , Histoplasmosis/tratamiento farmacológico , Histoplasmosis/epidemiología , Ganglios Linfáticos/microbiología , Piel/microbiología , Adolescente , Adulto , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Huesos/patología , Niño , Preescolar , Congo/epidemiología , Exposición a Riesgos Ambientales/efectos adversos , Femenino , Histoplasma/clasificación , Histoplasma/efectos de los fármacos , Histoplasmosis/diagnóstico , Humanos , Lactante , Itraconazol/uso terapéutico , Ganglios Linfáticos/patología , Masculino , Persona de Mediana Edad , Piel/patología , Adulto Joven
7.
Int J Infect Dis ; 112: 186-188, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34547485

RESUMEN

We report a case of black-grain eumycetoma co-localized with Mycobacterium tuberculosis infection, presenting as a painless leg abscess and associated with vertebral tuberculosis. The rare association of these two pathogens raises several challenges regarding foreseeable drug interactions, side effects, the most appropriate management, and the potential link between these two diseases.


Asunto(s)
Coinfección , Micetoma , Tuberculosis , Antifúngicos/uso terapéutico , Coinfección/diagnóstico , Coinfección/tratamiento farmacológico , Humanos , Micetoma/diagnóstico , Micetoma/tratamiento farmacológico , Columna Vertebral , Tuberculosis/complicaciones , Tuberculosis/diagnóstico , Tuberculosis/tratamiento farmacológico
9.
Front Microbiol ; 8: 334, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28326064

RESUMEN

Some cases of fungal infection remained undiagnosed, especially when the pathogens are uncommon, require specific conditions for in vitro growth, or when several microbial species are present in the specimen. Ultra-Deep Sequencing (UDS) could be considered as a precise tool in the identification of involved pathogens in order to upgrade patient treatment. In this study, we report the implementation of UDS technology in medical laboratory during the follow-up of an atypical fungal infection case. Thanks to UDS technology, we document the first case of gastro-intestinal basidiobolomycosis (GIB) due to Basidiobolus meristosporus. The diagnosis was suspected after histopathological examination but conventional microbiological methods failed to supply proof. The final diagnosis was made by means of an original approach based on UDS. DNA was extracted from the embedded colon biopsy obtained after hemicolectomy, and a fragment encompassing the internal transcribed spacer (ITS) rDNA region was PCR-amplified. An Amplicon library was then prepared using Genome Sequencer Junior Titanium Kits (Roche/454 Life Sciences) and the library was pyrosequenced on a GS Junior (Roche/454 Life Sciences). Using this method, 2,247 sequences with more than 100 bases were generated and used for UDS analysis. B. meristosporus represented 80% of the sequences, with an average homology of 98.8%. A phylogenetic tree with Basidiobolus reference sequences confirmed the presence of B. meristosporus (bootstrap value of 99%). Conclusion : UDS-based diagnostic approaches are ready to integrate conventional diagnostic testing to improve documentation of infectious disease and the therapeutic management of patients.

10.
Am J Trop Med Hyg ; 97(2): 567-574, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28722637

RESUMEN

Schistosomiasis remains one of the most prevalent parasitic diseases worldwide and the infection is frequently found in travelers and migrants. The European Network for Tropical Medicine and Travel Health conducted a sentinel surveillance study on imported schistosomiasis between 1997 and 2010. This report summarizes epidemiological and clinical data from 1,465 cases of imported schistosomiasis. Direct pathogen detection and serology were the main diagnostic tools applied. Of these, 486 (33%) cases were identified among European travelers, 231 (16%) among long-term expatriates, and 748 (51%) among non-European immigrants. Overall, only 18.6% of travelers had received pretravel advice; 95% of infections were acquired in the African region. On species level, Schistosoma mansoni was identified in 570 (39%) and Schistosoma haematobium in 318 (22%) cases; 57.5% of patients were symptomatic. Acute symptoms were reported in 27% of patients leading to earlier presentation within 3 months. Praziquantel was used in all patients to treat schistosomiasis. Many infections were detected in asymptomatic patients. In 47.4% of asymptomatic patients infection was detected by microscopy and in 39% by serology or antigen testing. Schistosomiasis remains a frequent infection in travelers and migrants to Europe. Travelers should be made aware of the risk of schistosomiasis infection when traveling to sub-Saharan Africa. Posttravel consultations particularly for returning expatriates are useful given the high potential for detecting asymptomatic infections.


Asunto(s)
Antihelmínticos/uso terapéutico , Praziquantel/uso terapéutico , Esquistosomiasis/diagnóstico , Adolescente , Adulto , África del Sur del Sahara/epidemiología , Anciano , Anciano de 80 o más Años , Animales , Niño , Preescolar , Europa (Continente)/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Prevalencia , Esquistosomiasis/tratamiento farmacológico , Esquistosomiasis/epidemiología , Migrantes/estadística & datos numéricos , Viaje/estadística & datos numéricos , Adulto Joven
11.
Trans R Soc Trop Med Hyg ; 99(1): 82-6, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15550267

RESUMEN

Malaria is the most frequent cause of fever among travellers returning from tropical countries. Each year about 7000 cases are notified in France, of which 90% are due to Plasmodium falciparum. We describe the case of a Caucasian female patient with no previous exposure to malaria in whom splenic infarction occurred during effective antimalarial treatment for initially uncomplicated acute malaria. Management was restricted to close clinical monitoring and analgesia (subcutaneous morphine). Imaging abnormalities resolved within a few months. We found seven other such cases in the literature. All seven patients were younger and splenic infarction occurred later than in the case we describe. Clinical outcome was favourable in all the cases. It is noteworthy that this rare complication can occur despite appropriate antimalarial prophylaxis and treatment. There are no known predictive signs. Clinicians must be aware that left hypochondrial pain occurring during treatment for acute malaria may be due to splenic infarction.


Asunto(s)
Malaria Falciparum/complicaciones , Infarto del Bazo/etiología , Enfermedad Aguda , Administración Oral , Adulto , Antimaláricos/administración & dosificación , Femenino , Humanos , Malaria Falciparum/diagnóstico por imagen , Malaria Falciparum/tratamiento farmacológico , Quinina/administración & dosificación , Infarto del Bazo/diagnóstico por imagen , Tomografía Computarizada por Rayos X/métodos
12.
J Travel Med ; 21(5): 361-3, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24912375

RESUMEN

Travel-related schistosomiasis can be detected in patients without symptoms of acute or chronic infection. A case of Schistosoma mekongi acquired in an endemic area of Laos and discovered unexpectedly from colon biopsies taken 5 years after infection is presented here. A literature review of previous cases of S. mekongi infection specifically associated with travelers is then presented.


Asunto(s)
Schistosoma/aislamiento & purificación , Esquistosomiasis/diagnóstico , Viaje , Adulto , Animales , Enfermedad Crónica , Colon/parasitología , Diagnóstico Diferencial , Femenino , Humanos , Laos , Esquistosomiasis/sangre
14.
Travel Med Infect Dis ; 9(2): 88-90, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21402495

RESUMEN

Apical lung opacity was diagnosed in an asymptomatic 30 year-old woman native of Central African Republic by routine chest X-ray. CT scan demonstrated an excavated pulmonary mass and revealed a simple hepatic cyst. Tuberculosis was suspected but mycobacterial cultures remained negative. Three months later, ultrasonography showed septations within the hepatic lesion suggestive of cystic echinococcosis. The detection of seric anti-Echinococcus antibodies was positive. Hepatic and pulmonary cysts were removed surgically and association with three-month course of albendazole resulted in a favorable outcome. Cystic echinococcosis is exceptional in Central Africa and to our knowledge never reported from the Central African Republic.


Asunto(s)
Equinococosis Hepática/diagnóstico , Equinococosis Pulmonar/diagnóstico , Adulto , Albendazol/uso terapéutico , Animales , Anticestodos/uso terapéutico , República Centroafricana , Diagnóstico Diferencial , Equinococosis Hepática/tratamiento farmacológico , Equinococosis Hepática/patología , Equinococosis Hepática/cirugía , Equinococosis Pulmonar/tratamiento farmacológico , Equinococosis Pulmonar/patología , Equinococosis Pulmonar/cirugía , Echinococcus granulosus/aislamiento & purificación , Femenino , Humanos , Radiografía Torácica , Tomografía Computarizada por Rayos X , Tuberculosis , Ultrasonografía
15.
Lancet Infect Dis ; 10(8): 556-70, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20670903

RESUMEN

More than 100 years after the discovery of human American trypanosomiasis by Carlos Chagas, our knowledge and management of the disease are profoundly changing. Substantial progress made by disease control programmes in most endemic areas contrasts with persisting difficulties in the Gran Chaco region in South America and the recent emergence of the disease in non-endemic areas because of population movements. In terms of pathogenesis, major discoveries have been made about the life cycle and genomics of Trypanosoma cruzi, and the role of the parasite itself in the chronic phase of the disease. From a clinical perspective, a growing number of arguments have challenged the notion of an indeterminate phase, and suggest new approaches to manage patients. New methods such as standardised PCR will be necessary to ensure follow-up of this chronic infection. Although drugs for treatment of Chagas disease are limited, poorly tolerated, and not very effective, treatment indications are expanding. The results of the Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT) trial in 2012 will also help to inform treatment. Mobilisation of financial resources to fund research on diagnosis and randomised controlled trials of treatment are international health priorities.


Asunto(s)
Enfermedad de Chagas/terapia , Autoinmunidad , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/epidemiología , Humanos , Pronóstico
16.
Presse Med ; 38(11): 1654-66, 2009 Nov.
Artículo en Francés | MEDLINE | ID: mdl-19349139

RESUMEN

International migration has led to the emergence of Chagas disease in industrialized countries, notably France. Clinicians should consider and test for Chagas disease in several situations: chronic cardiac and digestive manifestations in patients who lived (or whose parents lived) in an endemic area; pregnant woman who come from an endemic area and in the infant if the mother's serologic tests are positive; and more rarely, patients with a persistent fever who recently visited an endemic area. During the acute phase, diagnosis is confirmed by parasitological testing. During the chronic phrase, diagnosis remains serologic. The usefulness of PCR has not been determined. The recent recognition of the parasite's pathogenic role during the chronic phase has enlarged the indications for treatment. Today, all patients younger than 50 years with Chagas disease in the acute, chronic symptomatic or chronic asymptomatic phases should receive treatment, except for pregnant women, patients with hepatic or renal failure, or advanced cardiac or digestive manifestations. Treatment must be considered on an individual basis in patients older than 50 years. The frequency and seriousness of potential adverse events due to treatment require careful monitoring of the patient throughout treatment.


Asunto(s)
Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/terapia , Cardiomiopatía Chagásica/diagnóstico , Cardiomiopatía Chagásica/terapia , Enfermedad de Chagas/complicaciones , Protocolos Clínicos , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA